We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Aggressive Breast Cancer Identified with Fluorescent Technique

By LabMedica International staff writers
Posted on 21 Jul 2016
Ductal carcinoma in situ (DCIS) of the breast is the most common type of non-invasive breast cancer and in DCIS, epithelial cells proliferate within ducts, which are surrounded by a double layer of myoepithelial cells and basement membranes.

Although epidemiological studies propose aggressive and non-aggressive forms of ductal DCIS, they cannot be identified with conventional histopathology and because of this, to be safe, most patients undergo aggressive treatment.

Scientists at the University of Michigan Medical School (Ann Arbor, MI, USA) used a new method, called biomarker ratio imaging microscopy (BRIM), to evaluate the co-expression of biomarkers correlating and anti-correlating with breast cancer aggressiveness in a retrospective study of DCIS samples. More...
BRIM combines traditional microscope techniques that pathologists use to examine tissue with mathematical analysis. The technique compares levels of different biomarkers, which can be seen as different fluorescent colors in stained tissue under a microscope.

Fluorescence microscopy was performed using a TE2000-U inverted microscope (Nikon, Melville, NY, USA) and an Andor iXon camera (Andor Technology, Belfast, UK) with 100 W mercury lamp. The investigators looked at biopsy tissue samples from 23 patients with DCIS. They used fluorescent imaging, where the tissue samples are stained, to identify key biomarkers. Each biomarker was stained a different color. They then entered the images of the stained tissue samples into a computer that calculated the levels of different biomarkers in each pixel. In cancer, some biomarkers are present in high levels while others are less prolific. BRIM uses the ratio of these different levels to form an image of improved contrast.

The BRIM method found 22% of the samples had low ratios of cancer versus non-cancer biomarkers, suggesting those lesions were very slow-growing and non-aggressive. They note that an advantage of BRIM is that it uses several biomarkers rather than relying on only one. They decided which biomarkers to use after an extensive literature search. The authors concluded that the ability to stratify DCIS lesions and to identify potentially non-aggressive and aggressive lesions raises important issues in addressing overtreatment in breast cancer. BRIM is particularly attractive because it could be integrated into clinical pathology practices. Moreover, this approach may be useful in the cytologic study of aspirates in breast cancer and in peritoneal fluids in ovarian cancer. The study was published on June 1, 2016, in the journal Scientific Reports.

Related Links:
University of Michigan Medical School
Nikon
Andor Technology

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HbA1c Test
HbA1c Rapid Test
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.